DiaMedica Therapeutics Income Statement Analysis

Revenue, earnings, and profit margins in millions USD

Scroll to see more
DiaMedica Therapeutics Inc. income statement - Annual data in millions USD
BreakdownFY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018
Period EndingDec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018
Revenue & Gross Profit
Revenue0.000.000.000.000.000.000.50
Cost of Revenue0.000.000.000.000.000.000.00
Gross Profit0.000.000.000.000.000.000.00
Operating Expenses
Research & Development19.0613.117.848.778.217.904.52
Selling, General & Administrative7.628.166.164.884.493.692.74
Operating Expenses26.6821.2714.0013.6512.70-11.596.05
Operating Income-26.68-21.27-14.00-13.65-12.70-11.59-5.55
Other Income/Expense
Interest Income2.301.930.350.000.000.000.00
Interest Expense0.000.000.000.000.000.000.00
Other Income/Expense2.27-1.930.350.080.43-0.12-0.11
Income
Income Before Tax-24.41-19.34-13.65-13.56-12.27-10.62-5.65
Income Tax Expense0.030.040.030.030.030.030.08
Net Income-24.44-19.38-13.68-13.59-12.29-10.65-5.73
Net Income - Continuous Operations-24.44-19.38-13.68-13.590.000.000.00
Net Income - Discontinued Operations0.000.000.000.000.000.000.00
EBITDA-26.64-19.31-13.98-13.62-12.68-10.67-5.53
EBIT-24.41-19.34-14.00-13.65-12.70-10.62-5.55
Depreciation & Amortization0.040.030.030.020.02-0.020.00
Earnings Per Share
Basic EPS-1.00-1.00-1.00-1.00-1.00--1.00
Diluted EPS-1.00-1.00-1.00-1.00-1.00-1.00-1.00
Basic Shares Outstanding40.4032.5726.4420.7715.6811.997.74
Diluted Shares Outstanding40.4032.5726.4420.7715.6811.977.74